SPORE in Endometrial Cancer

这项子宫内膜癌卓越研究(孢子)专业计划是由圣路易斯的华盛顿大学、巴恩斯犹太医院的西特曼癌症中心和华盛顿大学医学院提交的。它包括四个研究项目，三个支持性核心，以及研究和职业发展计划。这项建议将基础和应用研究人员聚集在一起，进行旨在预防、诊断和治疗子宫内膜癌的创新和多样化的翻译调查。我们申请的四个项目经过精心设计，具有在五年内改变临床实践的巨大潜力。 项目1：FGFR2作为子宫内膜癌的治疗靶点 项目2：子宫内膜样癌预后的甲基化标志物 项目3：确定遗传性子宫内膜癌&导致躯体错配修复缺失的环境和遗传因素 项目4：ERK信号的新效应物及其在子宫内膜癌治疗中的潜在作用 这四个项目代表了精选的子宫内膜癌研究重点与华盛顿大学和我们的合作者的优势之间精心挑选的结合。我们选择关注的关键目标是：1)使用分子靶向疗法改善持续性或复发性子宫内膜癌患者的治疗，并确定早期辅助性生物疗法是否有望改善普通子宫内膜癌人群的预后；2)开发预后标记物，帮助指导患有最常见的子宫肿瘤--子宫内膜样癌的妇女的治疗；3)优化对那些患有遗传性子宫内膜癌的妇女的检测，以便她们及其高危家庭成员能够接受风险适当的(强化的)癌症监测；4)阐明ERK信号转导的新效应分子在子宫癌中的作用，并评估这些信号转导分子在子宫内膜癌治疗中的机会。 三个核心将支持这些项目：行政、组织与病理学和生物统计学。发展研究计划将支持一条继续确定和支持可能取代或改进现有项目的多样化研究的途径，职业发展计划将招募和支持致力于子宫内膜癌转化研究培训的候选人。

This Specialized Program of Research Excellence (SPORE) in Endometrial Cancer is submitted by Washington University in St. Louis, the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine. It includes four research projects, three supportive cores, and research and career development programs. This proposal brings together basic and applied investigators to conduct innovative and diverse translational investigations aimed at preventing, diagnosing and treating endometrial cancer. The four projects in our application have been carefully designed to have significant potential to change clinical practice within five years. Project 1: FGFR2 as therapeutic target in endometrial cancer Project 2: Methylation markers for prognosis in endometrioid endometrial cancers Project 3: Identifying inherited endometrial cancer & the environmental and genetic factors contributing to somatic loss of mismatch repair Project 4: Novel effectors of ERK signaling and their potential roles in the treatment of endometrial cancer The four projects represent carefully chosen marriages between selected endometrial cancer research priorities and the strengths of Washington University and our collaborators. The critical objectives that we have chosen to focus on are to: 1) improve the treatment of patients with persistent or recurrent endometrial cancer using a molecularly targeted therapy and determine if upfront adjuvant biologic therapies hold promise for improving outcomes in the general endometrial cancer population; 2) develop prognostic markers to help guide the treatment of women with the most common form of uterine tumors, endometrioid endometrial cancer; 3) optimize detection of those women with inherited forms of endometrial cancer so they and their at-risk family members can receive risk-appropriate (intensified) cancer surveillance; and 4) elucidate the role novel effectors of ERK signaling play in uterine cancer and assess opportunities for targeting these in the treatment of endometrial cancers. Three Cores will support these projects: Administration, Tissue & Pathology, and Biostatistics. The Developmental Research Program will support a pathway for continued identification and support of diverse research that could replace or improve current projects, and a Career Development Program will recruit and support candidates committed to training in translational research in endometrial cancer.